These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Verubecestat for Prodromal Alzheimer's Disease. Li S; Liu L; Selkoe D N Engl J Med; 2019 Jul; 381(4):388. PubMed ID: 31340105 [No Abstract] [Full Text] [Related]
3. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease. Doggrell SA Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903 [No Abstract] [Full Text] [Related]
4. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329 [TBL] [Abstract][Full Text] [Related]
5. Merck ends trial of potential Alzheimer's drug verubecestat. Hawkes N BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490 [No Abstract] [Full Text] [Related]
6. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506 [TBL] [Abstract][Full Text] [Related]
7. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948 [TBL] [Abstract][Full Text] [Related]